Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
AI and Machine Learning
Awards
Outsourcing Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CTLA-4
Pharma
Merck's Welireg surprisingly fails in first-line kidney cancer
Welireg's phase 3 flop in first-line kidney cancer comes as a surprise following two late-stage trial wins in the second-line and adjuvant settings.
Angus Liu
Apr 21, 2026 10:00am
BMS follows Roche, AstraZeneca into first-line liver cancer
Apr 11, 2025 1:53pm
BMS, Pfizer tout new standards in colorectal cancer subtypes
Jan 25, 2025 3:00pm
Astellas, Otsuka, Samsung Biologics—Fierce Pharma Asia
Oct 25, 2024 8:43am
Bristol Myers fails to beat AZ in stage 3 lung cancer
May 13, 2024 10:23am
BMS shoots for 1L liver cancer again with Opdivo, Yervoy combo
Mar 20, 2024 10:18am
